moderate-to-severe-eczemaatopic-dermatitisconjunctivitisINTRODUCTION. Atopic dermatitis (AD) is a chronic, relapsing, inflammatory, pruritic skin disease. More than 50% of cases begin during the first year of life and at least 80% of affected children have onset before the age of 5. A bimodal ...
has acted as a consultant and/or paid speaker for, and/or participated in research sponsored by, companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, Leo Pharma, Sanofi and ...
but the immunosuppressant mycophenolate mofetil in patients with moderate or severe atopic dermatitis not adequately controlled by topical treatments or not recommended, and alitretinoin to improve symptoms of hand eczema in patients with atopic dermatitis with hand eczema should...
Moreover, increasing efforts by pharmaceutical manufacturers to promote biological treatments for diseases such as acne, eczema, psoriasis, etc., which have a high prevalence rate in the country, have driven the bioproduction industry, and will generate hefty revenue for the U.S. dermatology biologi...
EczemaMonoclonal antibodiesBiologic therapyAdverse effectsSide effectsThe use of biologic agents as therapies for atopic diseases such as asthma and atopic dermatitis has increased greatly in recent years. The biological agents used to treat atopic diseases are for the most part monoclonal antibodies that...
We pursued a systematic review of the literature for studies assessing efficacy of NB‐UVB or biologics with endpoints including the Psoriasis Area and Severity Index (PASI) and the Eczema Area and Severity Index (EASI). Thirty‐four studies including 55 treatment regimens and 5,123 patients were...
Treatment with two intravenous doses of rituximab in six patients with severe atopic eczema produced significant improvement in clinical and histological parameters [125]. Therapeutic agents targeting IgE and IL-5 have been evaluated for the treatment of atopic dermatitis. Omalizumab is a monoclonal ...
(FDA) for adults, most of these therapies are now being evaluated in clinical trials for safety and efficacy in adolescents and children, expanding new treatment options for pediatric patients. The role of the FDA in drug approval is multifaceted from drug inception, ensuring that research, data...